Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from BriaCell Therapeutics ( (TSE:BCT) ).
BriaCell Therapeutics has reported promising clinical data at the 2025 ASCO Annual Meeting, showcasing robust overall survival and clinical benefits from its Bria-IMT and Bria-OTS studies in metastatic breast cancer. The Phase 2 study of Bria-IMT demonstrated a median overall survival of 17.3 months, surpassing outcomes of comparable patients in existing literature, and showed meaningful clinical benefits across various breast cancer subtypes. These results meet or exceed those of FDA-approved therapies, indicating significant potential for Bria-IMT in advancing cancer treatment options.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$18.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. The company is actively involved in creating treatments for metastatic breast cancer, with a market focus on addressing critical unmet needs in cancer treatment.
Average Trading Volume: 16,317
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$26.52M
Find detailed analytics on BCT stock on TipRanks’ Stock Analysis page.